



## Original Research Article

# Veterinary pharmacovigilance evaluation on impact of enrofloxacin administration on antioxidant status in broiler chicken

Veerapandian Sureshkumar, Ghadevaru Sarathchandra\* and Jayaramachandran Ramesh

Pharmacovigilance Laboratory for Animal Feed and Food Safety, Directorate of Centre for Animal Health Studies, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai-600 051, Tamil Nadu, India.

\*Corresponding author e-mail: [gsarathchandra@rediffmail.com](mailto:gsarathchandra@rediffmail.com)

## ABSTRACT

A veterinary pharmacovigilance study has been instigated in broiler chicken to explore the impact of enrofloxacin water medication on various antioxidants thereby to shed more light on the mechanism of oxidative stress produced by enrofloxacin. Day old broiler chicks were randomly divided into 4 groups each comprising 6 birds. Group I, control birds received non medicated water, while group II, III and IV were medicated with enrofloxacin @ recommended therapeutic dose 10mg/Kg body weight in drinking water for 5 successive days from 43rd to 47th day of age. On 1, 5 and 9 days after the last dose, respective treatment groups were sacrificed ethically and control birds were sacrificed at the end of the experiment. Serum, liver and muscle samples were collected and subjected to antioxidant analysis following standard procedures. Glutathione S-transferase, catalase and glutathione (GSH) levels were found to be significantly decreased in serum, muscle and liver in 1st and 5th day post treatment groups in comparison to control. Indeed, the antioxidant status showed restoration in tendency towards control values as evidenced by a non existence of significant difference between control and day 9 post treatments or day 5 and day 9 post treatment group. Despite significant fall in antioxidant status in serum, muscle and liver after enrofloxacin administration, the refurbishment of the same on 9th day of withdrawal period suggests that enrofloxacin is safe if medicated at recommended therapeutic dose and stipulated withdrawal period is stringently adhered.

### Keywords

Veterinary pharmacovigilance; enrofloxacin; antioxidant status; broiler chicken.

## Introduction

Fluoroquinolones stand for major class of antimicrobial agents advocated in food animals and poultry for the treatment of a wide range of infectious diseases. Enrofloxacin, a synthetic fluoroquinolone

chronic respiratory diseases, Colibacillosis, Salmonellosis and Fowl cholera in poultry (Anderson *et al.*, 2003, Martinez *et al.*, 2006, Papich, M.G. and Riviere, 2009). Gurbay *et al.*, (2001)

postulated that during metabolic transformation of enrofloxacin into pharmacologically active metabolite ciprofloxacin in liver (Prescott *et al.*, 2000; Taccetti *et al.*, 2008; Papich, M.G. and Riviere, 2009), free radical intermediates are generated and resulted in lipid peroxidation. Further, Martinez-Cayuela (1998) opined that enrofloxacin residues may occur in meat, milk and eggs, generate free radicals owing to its metabolism and interact with other medicated drugs (Ershov *et al.*, 2001; Carreras *et al.*, 2004; Sureshkumar *et al.*, 2004).

Fluoroquinolones are considered relatively well tolerated than the other commonly used antimicrobial agents. However, it has been reported that they are also associated with a low incidence of adverse effects related to gastrointestinal, skin, hepatic, and central nervous system functions, and phototoxicity (Hooper, *et al.*, 1985). Further, enrofloxacin administration in broiler chicken resulted in significant fall in lymphocyte count (Sureshkumar *et al.*, 2012) and reduction in haemagglutination inhibition (HI) titre and associated histopathological changes in lymphoid organs (Sureshkumar *et al.*, 2013). Literature evidences indicated that these adverse effects might be attributed to free radical formation (Wagai and Tawara, 1991; Hayem *et al.*, 1994) and very little reports have elucidated the mechanism of toxicity of fluoroquinolones (Gurbay *et al.*, 2001).

Glutathione S-transferase (GST) is the key antioxidant defends cells against toxicants by conjugating the thiol group of the glutathione to electrophilic xenobiotics, thus GST levels divulge the antioxidant ability of the body. Glutathione (GSH) detoxifies the xenobiotics by removing

hydroperoxides, and maintaining the oxidation state of protein sulfhydryls (Akerboom and Sies, 1981). Oxidative stress arises when free radicals, lipid hydroperoxides, aldehydes, hydrogen peroxides react with cellular constituents such as thiols and lipids and alter the antioxidant defense systems (Keyse and Tyrell, 1989; Wang and Huang, 1994; Liu *et al.*, 2001). In spite of the literature evidences available on the incidence of antibiotics to cause oxidative stress in other animal species (Salyi *et al.*, 1990; Mezes *et al.*, 1992), data in poultry is scanty (Altinordulu and Eraslan, 2009).

Hence a veterinary pharmacovigilance study has been instigated in broiler chicken to explore the impact of enrofloxacin water medication on various antioxidants thereby to shed more light on the mechanism of oxidative stress produced by enrofloxacin.

## **Materials and Methods**

### **Enrofloxacin water medication**

Institutional Animal Ethics Committee, Madras Veterinary College, TANUVAS has accorded permission for the biological trial. Twenty four one-day-old broiler chicks (Broiler strain B<sub>1</sub>) were randomly grouped into control (I) and treatment (II, III and IV) and maintained under standard management conditions. Treatment groups were medicated with enrofloxacin @ recommended therapeutic dose 10mg/Kg body weight, in drinking water for 5 successive days, while control birds received non medicated water (Knoll *et al.*, 1999, Sureshkumar *et al.*, 2013). The pulsed water medication was given as described by Charleston *et al.*, (1998).

### **Antioxidant enzyme analysis**

On 1, 5 and 9 days after the last dose, respective treatment groups were sacrificed ethically and control birds were sacrificed at the end of the experiment. Serum, liver and muscle samples were collected and subjected to antioxidant enzyme analysis. Tissue sample of 100mg was homogenized in 1 mL of phosphate buffer (pH 8) and centrifuged at 10000rpm for 5min at 4°C. The supernatant was used as enzyme/protein sample for further analysis. Glutathione S-transferase (GST) assay was carried out following the methodology of Habig et al. (1974); Mannervik and Danielson, (1988); Wilce and Parker, (1994). Glutathione (GSH) assay was carried out as described by Akerboom and Sies, (1981). Catalase (CAT) activity was estimated by the method of Sinha (1972). Statistical analysis was carried out as per Snedecor and Cochran (1994).

### **Results and Discussion**

In liver, a significant decrease ( $p<0.01$ ) in GST and GSH level was noticed at all the time points evaluated during the withdrawal period when compared to that of control. On the other hand, a statistically insignificant difference existed between day 1 and day 5 post treatment.

Muscle GST level was significantly ( $p<0.05$ ) decreased on day 1 and day 5 post treatment. However, on day 9 post treatment it was statistically insignificant when compared to that of control. Muscle GSH level was significantly decreased ( $p<0.01$ ) at all the time points evaluated during the withdrawal period, except on day 9 post treatment as indicated by insignificant difference between day 5 and day 9 post treatment.

Serum GSH activity was significantly decreased ( $p<0.01$ ) on day 1 and day 5 post treatment. However, on 9<sup>th</sup> day post treatment the GSH level was statistically insignificant in comparison to control. A significant decrease ( $p<0.01$ ) in serum GST level was noticed on day 5 post treatment. However, similar to that of muscle statistically insignificant difference was noticed between day 9 post treatment and control.

Catalase activity in liver and muscle was significantly decreased ( $p<0.01$ ) on day 1 and day 5 post treatment from that of control. However, a trend in increase in the CAT level was noticed on day 9 post treatment as indicated by a statistically insignificant difference between day 9 post treatment and control. Serum CAT activity was significantly reduced ( $p<0.01$ ) at all the time points evaluated during the withdrawal period. However, a trend in increase in the CAT level was noticed on day 9 post treatment as evidenced by a insignificant difference from that of day 1 post treatment (Table 1).

In the present study, a significant decrease in GST and GSH level in liver, muscle and serum is suggestive of depletion of glutathione store, which could be attributed due to free radical generation by enrofloxacin and its metabolite ciprofloxacin (Gurbay *et al.*, 2001; Altinordulu and Eraslan, 2009). The free radicals thus generated are scavenged by GSH by donating electrons, thereby the balance between GSH-reduced glutathione and GSH-oxidized glutathione is disturbed (Sies, 1993).

Evaluation of CAT activity in liver and muscle showed a significant difference on day 1 and day 5 post treatment, which is in agreement with Benzer *et al.* (2009).

**Table.1** Effect of enrofloxacin administration (10mg/Kg body weight, in drinking water for 5 successive days) on antioxidants status (Mean±SE, n=6)

Parameters	Tissues	Control	Day 1 Post Treatment	Day 5 Post Treatment	Day 9 Post Treatment
GST (nmoles/mL/min)	Liver	5.87 <sup>a</sup> ± 0.26	2.82 <sup>c</sup> ± 0.14	3.02 <sup>c</sup> ± 0.12	4.36 <sup>b</sup> ± 0.13
	Muscle	2.08 <sup>x</sup> ± 0.14	1.70 <sup>yz</sup> ± 0.06	1.62 <sup>z</sup> ± 0.14	1.96 <sup>xy</sup> ± 0.06
	Serum	1.96 <sup>a</sup> ± 0.24	1.47 <sup>abc</sup> ± 0.19	0.64 <sup>c</sup> ± 0.04	1.62 <sup>ab</sup> ± 0.31
GSH (nmoles/mL)	Liver	39.71 <sup>a</sup> ± 1.18	8.36 <sup>c</sup> ± 0.94	5.34 <sup>c</sup> ± 0.25	16.70 <sup>b</sup> ± 0.90
	Muscle	50.16 <sup>a</sup> ± 0.99	23.15 <sup>c</sup> ± 1.23	39.23 <sup>b</sup> ± 0.57	42.12 <sup>b</sup> ± 0.58
	Serum	45.31 <sup>a</sup> ± 1.48	11.58 <sup>c</sup> ± 0.51	35.14 <sup>b</sup> ± 1.16	41.16 <sup>a</sup> ± 1.20
Catalase (µmoles of H <sub>2</sub> O <sub>2</sub> consumed/min/g protein)	Liver	49.46 <sup>a</sup> ± 0.96	44.09 <sup>b</sup> ± 0.47	33.35 <sup>c</sup> ± 0.87	47.99 <sup>a</sup> ± 0.55
	Muscle	43.40 <sup>a</sup> ± 0.96	21.12 <sup>c</sup> ± 0.73	27.50 <sup>b</sup> ± 0.80	46.46 <sup>a</sup> ± 0.60
	Serum	59.84 <sup>a</sup> ± 1.03	38.66 <sup>b</sup> ± 0.79	28.37 <sup>c</sup> ± 0.86	36.77 <sup>b</sup> ± 0.67

Means bearing different superscript (x,y,z / a,b,c) within the row differ significantly (p<0.05 / p<0.01)

Decrease in CAT activity is suggestive of free radicals formation following the enrofloxacin administration. This is in accordance with Altinordulu and Eraslan (2009), who demonstrated that CAT activity is diminished in the event of hydrogen peroxide radical formation. However, a trend in restoration of CAT level was noticed on day 9 post treatment as represented by a statistically insignificant difference between day 9 post treatment and control.

*In vivo*, enrofloxacin is de-ethylated into its primary metabolite ciprofloxacin by liver microsomal enzymes of the cytochrome P450 family (Stratton, 1998, Taccetti *et al.*, 2008, Altinordulu and Eraslan, 2009). Further, ciprofloxacin is metabolized by alteration to the piperazine side chain (Sorgel, 1989). Several authors have speculated that consequent to the metabolism of enrofloxacin and ciprofloxacin, free radicals are generated, and resulted in lipid peroxidation (Martinez-Cayuela, 1998; Gurbay *et al.*, 2001; Altinordulu and Eraslan, 2009). These hypotheses are very well portrayed

in the present findings as evidenced by significant decrease in GST, GSH and CAT level in liver, muscle and serum of broiler chicken administered with enrofloxacin. Vaccaro *et al.* (2003) reported that oxidation of ciprofloxacin by CYP450 leads to formation of reactive intermediates. As a sequel, a series of subsequent deleterious reactions occurred (Nie *et al.*, 2008).

The significant fall in antioxidants enzymes after enrofloxacin medication followed by its restoration during the withdrawal period could be attributed to the depletion of the enrofloxacin residues from liver and muscle during the withdrawal period. This proposition is substantiated by Chattha *et al.* (2008), who observed that enrofloxacin residues were washed out in 9 days whilst its major metabolite ciprofloxacin was washed out in 8 days in chicken meat. Further, Petrovic *et al.* (2006) showed that a 4 days of withdrawal period after enrofloxacin administration resulted in decrease in enrofloxacin residues to a tolerable level in the broiler meat and liver. While, San

Martin et al. (2010) demonstrated that based on the European Union maximum residue limits (EU MRLs) of 100 µg/Kg (muscle) and 200 µg/ Kg (liver), the withdrawal time was 5 days, and when Japan MRL was considered (10 µg/Kg.), the withdrawal time was found to be 8 days in broiler chicken. From these reports it is evident that enrofloxacin residues were high during the earlier days of the withdrawal period, whereas on day 9 post treatment it was below 10 µg/Kg. Same trend was reflected in the antioxidant status of the liver, muscle and serum as evidenced by corresponding restoration in the antioxidants level on 9th day of the withdrawal period.

Despite significant fall in antioxidant status in serum, muscle and liver after enrofloxacin administration, the refurbishment of the same on 9th day of withdrawal period suggests that enrofloxacin is safe if administered at recommended therapeutic dose and stipulated withdrawal period is adhered. Thereby it avoids untoward adverse drug reactions and residues.

### **Author's contributions**

Component of the Ph.D. thesis work of the first author V. Sureshkumar, submitted to Tamil Nadu Veterinary and Animal Sciences University, Chennai-51. G. Sarathchandra was the Chairman and planned the trial. V. Sureshkumar conducted the experimental trial. J.Ramesh involved in sampling. G.Sarathchandra and V. Sureshkumar processed the data, arranged and corrected the article. All authors proof read and accepted the final article.

### **Acknowledgements**

The Authors are highly grateful to Drugs and Pharmaceutical Research Programme, Department of Science and Technology, Government of India, New Delhi, for the financial support as part of the DST scheme entitled "A National Facility for Pharmacovigilance on Drug Residue and other Toxic Xenobiotics including Genetically Manipulated Organisms in Veterinary Products" at Pharmacovigilance Laboratory for Animal Feed and Food Safety, DCAHS, TANUVAS, Chennai-600 051.

### **Competing interests**

Authors declare that they have no competing interest.

### **References**

- Akerboom, T.P., and Sies, H. 1981. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. *Methods. Enzymol.* **77**: 373-382.
- Altinordulu, S., and Eraslan, G. 2009. Effects of some quinolone antibiotics on malondialdehyde levels and catalase activity in chicks. *Food. Chem. Toxicol.* **47**: 2821-2823.
- Anderson, A.D., J.M. Nelson, S. Rossiter and Angulo, F.J. 2003. Public health consequences of use of antimicrobial agents in food animals in the United States. *Microb. Drug. Resist.* **9**: 373-379.
- Benzer, F., A. Kilic, S. Yilmaz, M. Erisir, N. Timurkaan and Ertas, H.B. 2009. Influence of enrofloxacin administration on oxidative stress and antioxidant enzyme activities of experimentally infected broilers with *Salmonella enterica* serovar enteritidis. *J. New World Sci. Acad.* **4**: 24-33.

- Carreras, I., M. Castellari, J.A.Garcia Regueiro, L. Guerrero, E. Esteve-Garcia and Sarraga, C. 2004. Influence of enrofloxacin administration and  $\alpha$ -tocopheryl acetate supplemented diets on oxidative stability of broiler tissues. *Poult. Sci.* 83: 796-802.
- Charleston, B., J.J. Gate, I.A. Aitken, B. Stephan and Froyman, R. 1998. Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against *Escherichia coli* infection in chickens. *Antimicrob. Agents Chemother.* 42: 83-87.
- Chattha, F.A., R. Nawaz and Ali Munawar, M. 2008. The study of withdrawal period of enrofloxacin and its residues in poultry foods. *J. Chem. Soc. Pak.* 30: 155-157.
- Ershov, E., M. Bellaiche, V. Hanji, S. Soback, M. Gips and Shlosberg, A. 2001. Interaction of fluoroquinolones and certain ionophores in broilers: effect on blood levels and hepatic cytochrome P450 monooxygenase activity. *Drug Metabol. Drug Interact.* 18: 209-219.
- Gurbay, A., B. Gonthier, D. Daveloose, A. Favier and Hincal, F. 2001. Microsomal metabolism of ciprofloxacin generates free radicals. *Free Radic. Biol. Med.* 30: 1118-1121.
- Habig W.H., M.J. Pabst and Jakoby, W.B. 1974. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. *J. Biol. Chem.* 249: 7130-7139.
- Hayem, G., P.X. Petit, M. Levacher, C. Gaudin, M.F. Kahn and Pocidalò, J.J. 1994. Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. *Antimicrob. Agents Chemother.* 38: 243-247.
- Hooper, D.C., and Wolfson, J.S. 1985. The fluoroquinolones: pharmacology, clinical uses, and toxicities in human. *Antimicrob. Agents Chemother.* 28: 716-721.
- Keyse, S.M., and Tyrell, R.M. 1989. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide and sodium arsenite. *Proc. Natl. Acad. Sci. USA.* 86: 99-103.
- Knoll, U., G. Glunder and Kietzmann, M. 1999. Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. *J. Vet. Pharmacol. Therap.* 22: 239-246.
- Liu, S.X., M. Athar, I. Lippai, C. Waldren and Hei, T.K. 2001. Induction of oxygen radicals by arsenic: implications for mechanism of genotoxicity. *Proc. Natl. Acad. Sci. USA.* 98:1643-1648.
- Mannervik, B., and Danielson, U.H. 1988. Glutathione transferases - structure and catalytic activity. *CRC Crit. Rev. Biochem.* 23: 283-337.
- Martinez, M., P. McDermonnt and Walker, R. 2006. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. *Vet. J.* 172: 10-28.
- Martinez-Cayuela, M., 1998.. Toxicity of xenobiotics mediated by oxygen free radicals. *Ars Pharm.* 39: 5-18.
- Mezes, M., G. Salyi, G. Banhidi and Szeberenyi, S. 1992. Effect of acute salinomycin - tiamulin toxicity on the lipid peroxide and antioxidant status of broiler chicken. *Acta Vet. Hung.* 40: 251-257.
- Nie, X., X. Wang, J. Chen, V. Zitko and An, T. 2008. Response of the freshwater alga *Chlorella vulgaris* to trichloroisocyanuric acid and ciprofloxacin. *Environ. Toxicol. Chem.* 27: 168-173.
- Papich, M.G., and Riviere, J.E. 2009. Fluoroquinolone antibacterial drugs. In: Riviere, J.E. and Papich, M.G., editors, *Veterinary Pharmacology and Therapeutics*. 9<sup>th</sup> edition. Wiley-Blackwell, Iowa State University Press, USA. pp.983-1011.

- Petrovic, J., M. Baltic, V. Cupic, S. Stefanovi and Dragica, S. 2006. Residues of enrofloxacin and its main metabolite ciprofloxacin in broiler chickens. *Acta Vet. (Beograd)*. 56: 497-506.
- Prescott, J.F., J.D. Baggot and Walker, R.D. 2000. Fluoroquinolones, In: Prescott, J.F., Baggot, J.D. and Walker, R.D., editors, *Antimicrobial Therapy in Veterinary Medicine*, 3<sup>rd</sup> edition. Ames: Iowa State University Press. pp. 315-339.
- Salyi, G., M. Mezes and Banhidi, G. 1990. Changes in the lipid peroxide status of broiler chickens in acute monensin poisoning. *Acta Vet. Hung.* 38: 263-270.
- San Martin, B., J. Cornejo, L. Lapierre, D. Iraguen, F. Perez, H. Hidalgo and Andre, F. 2010. Withdrawal time of four pharmaceutical formulations of enrofloxacin in poultry according to different maximum residues limits. *J. Vet. Pharmacol. Ther.* 33: 246-251.
- Sies, H., 1993. Strategies of antioxidant defense. *Eur. J. Biochem.* 215: 213-219.
- Sinha, A., 1972. Catalase - An extra ordinary enzyme. *Science.* 210: 71-82.
- Snedecor, G.W., and Cochran, W.G. 1994. *Statistical methods*, 8th Edn., Ames: Iowa State University Press.
- Sorgel, F., 1989. Metabolism of gyrase inhibitors. *Rev. Infect. Dis.* 11: S1119-S1129.
- Stratton, C.W., 1998. The safety profile of fluoroquinolones. *Antimicrob. Infect. Dis. Newsletter.* 17: 57-60.
- Sureshkumar, V., G. Saratchandra and Ramesh, J. 2013. Effect of enrofloxacin on Zootechnical performance, behaviour and immunohistopathological response in broiler chicken. *Vet. World.* 6:337-342.
- Sureshkumar, V., G. Saratchandra, J. Ramesh, S. Vairamuthu, P. Thejomoorthy and Hariharan, P. 2012. The effect of enrofloxacin administration on haematological profile in broiler chicken - A safety pharmacology study. *The Indian J. Field Veterinarians.* 8: 20-24.
- Sureshkumar, V., K.V. Venkateswaran and Jayasundar, S. 2004. Interaction between enrofloxacin and monensin in broiler chickens. *Vet. Hum. Toxicol.* 46: 242-245.
- Taccetti, G., S. Campana, A. Neri, V. Boni and Festini, F. 2008. Antibiotic therapy against *Pseudomonas aeruginosa* in cystic fibrosis. *J. Chemother.* 20: 166-169.
- Vaccaro, E., M. Giorgi, V. Longo, G. Mengozzi and Cervasi, P.G. 2003. Inhibition of cytochrome P450 enzymes by enrofloxacin in the sea bass (*Dicentrarchus labrax*). *Aquat. Toxicol.* 62: 27-33.
- Wagai, N., and Tawara, K. 1991. Quinolone antibacterial agent induced cutaneous phototoxicity: ear swelling reactions in BALB/c mice. *Toxicol. Lett.* 58: 215-223.
- Wang, T.S., and Huang, H. 1994. Active oxygen species are involved in the induction of micronuclei in XRS-5 cells. *Mutagenesis.* 9: 253-257.
- Wilce, M.C.J., and Parker, M.W. 1994. Structure and function of Glutathione S-transferases. *Biochem. Biophys. Acta.* 1205: 1-18.